Pharmacogenetic Factors and Side Effects of Metoclopramide and Diphenhydramine — MalD

Drug Metabolism, Poor, CYP2D6-RELATED Clinical Trial

Official title:
Pharmacogenetic Factors and Side Effects of Metoclopramide and Diphenhydramine

Status Terminated

Clinical Trial Summary

Pharmacokinetic of Metoclopramide (MCP) in correlation to polymorphisms of CYP2D6 and Dopamine-D2-Receptor. Pharmacokinetic of Diphenhydramine (DPH) in correlation to polymorphisms of CYP2D6

Clinical Trial Description

n/a

Study Design

Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science

Related Conditions & MeSH terms

Drug Metabolism, Poor, CYP2D6-RELATED
Metabolism, Inborn Errors

Clinical Trial Details

NCT number	NCT01289938
Study type	Interventional
Source	University Hospital Tuebingen
Contact
Status	Terminated
Phase	Phase 1
Start date	July 2009
Completion date	June 2015

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT02191358` - YouScript IMPACT Registry	N/A
Completed	`NCT02378220` - Pharmacogenetic Testing Among Home Health Patients	N/A
Recruiting	`NCT05981573` - Assessment of Methadone Dose Taken Using Electrochemistry
Completed	`NCT02428660` - Drug & Gene Interaction Risk Analysis With & Without Genetic Testing Among Patients Undergoing MTM	N/A
Not yet recruiting	`NCT06322238` - Pharmacogenetic Panel to Prevent Adverse Drug Reactions in Daily Primary Care Practice:	Phase 2